ELUT · Elutia Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.31M | - | $1.47M | $3.21M | $3.57M | - | $3.18M | $3.49M | $3.29M | - |
| Gross Profit | $1.80M | - | $1.85M | $3.06M | $2.46M | - | $2.74M | $2.80M | $2.84M | - |
| R&D | $1.97M | - | $1.09M | $1.46M | $905.0K | - | $778.0K | $1.00M | $557.0K | - |
| SG&A | $4.09M | - | $3.52M | $3.69M | $3.87M | - | $4.52M | $4.69M | $2.76M | - |
| Total Operating Expenses | $8.15M | - | $7.06M | $12.93M | $10.38M | - | $12.97M | $11.31M | $10.21M | - |
| D&A | $330.0K | $100.0K | - | - | $868.0K | $100.0K | - | - | $864.0K | - |
| Operating Income | ($6.35M) | - | ($5.21M) | ($9.88M) | ($7.92M) | - | ($10.23M) | ($8.51M) | ($7.37M) | - |
| Interest Expense | - | - | $265.0K | $518.0K | $1.31M | - | $1.45M | $1.41M | $1.45M | - |
| Income Tax | $70.0K | - | $8.0K | $8.0K | $8.0K | - | $8.0K | ($11.0K) | $12.0K | - |
| Net Income | ($7.47M) | - | ($3.87M) | ($9.61M) | ($3.93M) | - | $1.29M | ($28.18M) | ($9.75M) | - |
| EPS - Basic | ($0.17) | - | ($0.09) | ($0.23) | ($0.10) | - | $0.03 | ($1.13) | ($0.57) | - |
| EPS - Diluted | ($0.17) | - | ($0.19) | ($0.26) | ($0.21) | - | ($0.33) | ($1.13) | ($0.57) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.49M | $36.35M | $4.72M | $8.50M | $17.36M | $13.24M | $25.74M | $18.19M | $12.55M | $19.28M |
| Accounts Receivable | $2.07M | $1.73M | $3.55M | $3.15M | $2.86M | $2.28M | $2.93M | $3.52M | $4.41M | $3.26M |
| Inventory | $2.66M | $2.62M | $2.01M | $5.24M | $4.29M | $3.91M | $3.63M | $3.12M | $3.05M | $3.85M |
| Accounts Payable | $3.87M | $4.79M | $6.60M | $6.07M | $4.52M | $4.15M | $5.07M | $3.14M | $4.16M | $2.29M |
| Current Assets | $48.59M | $55.82M | $18.38M | $22.28M | $30.02M | $26.17M | $37.32M | $30.35M | $23.99M | $31.25M |
| Total Assets | $55.21M | $62.35M | $29.41M | $33.85M | $39.30M | $36.13M | $48.41M | $41.90M | $35.36M | $43.43M |
| Current Liabilities | $23.73M | $25.14M | $41.33M | $37.95M | $36.85M | $37.80M | $39.68M | $39.81M | $38.07M | $43.04M |
| Long-term Debt | - | - | $21.10M | $21.37M | $21.76M | $22.60M | $22.64M | $18.87M | $19.74M | $20.36M |
| Total Liabilities | $32.68M | $34.68M | $73.33M | $75.69M | $75.76M | $82.39M | $88.64M | $106.24M | $85.66M | $82.03M |
| Stockholders' Equity | $22.53M | $27.67M | ($43.92M) | ($41.84M) | ($36.46M) | ($46.26M) | ($40.24M) | ($64.34M) | ($50.30M) | ($38.60M) |
| Retained Earnings | ($183.68M) | ($176.21M) | ($247.00M) | ($243.14M) | ($233.53M) | ($229.59M) | ($220.53M) | ($221.82M) | ($193.64M) | ($175.64M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.83M) | - | - | - | ($8.88M) | - | - | - | ($2.64M) | - |
| Investing Cash Flow | ($34.0K) | - | - | - | ($278.0K) | - | - | - | ($15.0K) | - |
| Financing Cash Flow | $3.0K | - | - | - | $13.28M | - | - | - | ($4.07M) | - |
| CapEx | $459.0K | - | - | - | $278.0K | - | - | - | $15.0K | - |
| Free Cash Flow | ($8.29M) | - | - | - | ($9.16M) | - | - | - | ($2.66M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q3 '23 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.11 | - | - | - | 2.33 | - | - | - | 0.27 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | 0.6% | - | - | - |
| Return on assets | -13.5% | - | -13.2% | -28.4% | -10.0% | - | 2.7% | -67.2% | -27.6% | - |
| Return on equity | -33.2% | - | 8.8% | 23.0% | 10.8% | - | -3.2% | 43.8% | 19.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.05 | 2.22 | 0.44 | 0.59 | 0.81 | 0.69 | 0.94 | 0.76 | 0.63 | 0.73 |
| Quick ratio | 1.94 | 2.12 | 0.40 | 0.45 | 0.70 | 0.59 | 0.85 | 0.68 | 0.55 | 0.64 |
| Cash ratio | 1.20 | 1.45 | 0.11 | 0.22 | 0.47 | 0.35 | 0.65 | 0.46 | 0.33 | 0.45 |
| Leverage | ||||||||||
| Debt / Equity | - | - | -0.48 | -0.51 | -0.60 | -0.49 | -0.56 | -0.29 | -0.39 | -0.53 |
| Debt / Assets | - | - | 0.72 | 0.63 | 0.55 | 0.63 | 0.47 | 0.45 | 0.56 | 0.47 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -19.7x | -19.1x | -6.0x | - | -7.1x | -6.0x | -5.1x | - |
| Equity multiplier | 2.45 | 2.25 | -0.67 | -0.81 | -1.08 | -0.78 | -1.20 | -0.65 | -0.70 | -1.13 |
| Liabilities / Assets | 0.59 | 0.56 | 2.49 | 2.24 | 1.93 | 2.28 | 1.83 | 2.54 | 2.42 | 1.89 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.49 | - | 0.73 | 0.61 | 0.83 | - | 0.88 | 1.12 | 1.08 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 739d | - | 499d | 597d | 438d | - | 417d | 326d | 339d | - |
| Days payable outstanding | 1077d | - | 1638d | 692d | 461d | - | 582d | 328d | 462d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.0x | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -26.7% | - | -32.4% | 9.3% | - | - | -3.5% | 185.6% | -43.7% | - |
| Operating income growth (YoY) | 19.9% | - | 49.1% | -16.0% | - | - | -38.8% | 6.3% | 5.4% | - |
| Net income growth (YoY) | -89.9% | - | - | 65.9% | - | - | - | -165.3% | 1.6% | - |
| EPS growth (YoY) | 19.0% | - | 42.4% | 77.0% | - | - | 42.1% | -73.8% | 21.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 9.5% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -9.1% | 35.0% | - | -19.8% | 20.0% | -190.8% | -370.9% | -666.9% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ELUTIA INC. against the 5 most active filers in the same SIC group.